AR056487A1 - UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA - Google Patents

UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA

Info

Publication number
AR056487A1
AR056487A1 ARP060103826A ARP060103826A AR056487A1 AR 056487 A1 AR056487 A1 AR 056487A1 AR P060103826 A ARP060103826 A AR P060103826A AR P060103826 A ARP060103826 A AR P060103826A AR 056487 A1 AR056487 A1 AR 056487A1
Authority
AR
Argentina
Prior art keywords
neoplasm
treat
virus
oncolitical
mammer
Prior art date
Application number
ARP060103826A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR056487A1 publication Critical patent/AR056487A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

Para tratar o aliviar neoplasmas, y mejorar la eficacia de virus oncolíticos, que comprenden administrarle un virus oncolítico a un mamífero que sufre un neoplasma, y subsiguientemente administrarle un inmunoestimulante, también se proveen métodos para incrementar el reconocimiento inmune de células neoplásticas.
ARP060103826A 2005-08-31 2006-08-31 UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA AR056487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71328705P 2005-08-31 2005-08-31

Publications (1)

Publication Number Publication Date
AR056487A1 true AR056487A1 (es) 2007-10-10

Family

ID=37808428

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103826A AR056487A1 (es) 2005-08-31 2006-08-31 UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA

Country Status (13)

Country Link
US (1) US20070071723A1 (es)
EP (1) EP1922085A4 (es)
JP (1) JP2009504687A (es)
CN (1) CN101304761A (es)
AR (1) AR056487A1 (es)
AU (1) AU2006287052B2 (es)
CA (2) CA2825762A1 (es)
IL (1) IL188816A0 (es)
MX (1) MX2008002743A (es)
SG (1) SG149870A1 (es)
TW (1) TW200812614A (es)
WO (1) WO2007025365A1 (es)
ZA (1) ZA200800246B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
WO2009135614A2 (en) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Use of a virus regimen for the treatment of diseases
ES2576036T3 (es) 2009-03-16 2016-07-05 Mcmaster University Métodos de vacunación
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
CN103260650B (zh) * 2010-10-20 2015-05-06 西奈山医学院 使用髓源抑制细胞治疗肿瘤的方法和组合物
JP5897700B2 (ja) * 2011-04-12 2016-03-30 インターベット インターナショナル ベー． フェー． 腫瘍崩壊におけるトリメタニューモウイルス
US10238698B2 (en) * 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
US10363293B2 (en) 2013-02-21 2019-07-30 Turnstone Limited Partnership Vaccine composition
EP3441084A1 (en) * 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
KR20170098957A (ko) * 2015-01-16 2017-08-30 시티 오브 호프 세포 침투성 항체
GB201504251D0 (en) 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN108338994A (zh) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
CN113811318A (zh) * 2019-05-09 2021-12-17 萨特治疗学有限公司 使用树突细胞的溶瘤病毒递送

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113584A1 (en) * 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting

Also Published As

Publication number Publication date
CA2825762A1 (en) 2007-03-08
IL188816A0 (en) 2008-08-07
TW200812614A (en) 2008-03-16
CN101304761A (zh) 2008-11-12
ZA200800246B (en) 2009-08-26
WO2007025365A1 (en) 2007-03-08
CA2621127A1 (en) 2007-03-08
CA2621127C (en) 2014-02-25
AU2006287052B2 (en) 2009-03-12
JP2009504687A (ja) 2009-02-05
US20070071723A1 (en) 2007-03-29
SG149870A1 (en) 2009-02-27
EP1922085A1 (en) 2008-05-21
EP1922085A4 (en) 2009-12-30
AU2006287052A1 (en) 2007-03-08
MX2008002743A (es) 2008-03-26

Similar Documents

Publication Publication Date Title
AR056487A1 (es) UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA
EP4286009A3 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
AR059482A1 (es) Uso de supresion inmune local para potenciar terapia viral oncolitica
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
NO20072733L (no) Doseformer
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
BR112017020973A2 (pt) método para tratar câncer em um paciente
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
PH12015502112A1 (en) Cancer treatment using antibodies that bind cell surface grp78
WO2011130566A3 (en) Method for treating solid tumors
EA201991202A1 (ru) Системы и способы улучшенного поддержания высокоэффективной конфигурации с обращенным полем и нагрева электронов посредством высших гармоник быстрых волн в высокоэффективной конфигурации с обращенным полем
DK1755659T3 (da) Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
EP4197551A3 (en) Adoptive cell transfer and oncolytic virus combination therapy
EA201790913A1 (ru) Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.
MX2018003757A (es) Composiciones y metodos para producir celulas dendriticas.
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
WO2012078867A3 (en) Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
EA202090548A1 (ru) Вакцина для применения в профилактике и/или лечении заболевания
WO2008118785A3 (en) Methods for treating depression using immediate-impact treatments and d-cycloserine
MX2020001451A (es) Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.
MX2018009506A (es) Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.

Legal Events

Date Code Title Description
FB Suspension of granting procedure